Factors influencing the inhibition of protein kinases

Brockhoff, Marielle; Hau, Jean-Christophe; Fontana, Patrizia; Zimmermann, Catherine; Pover, Alain De; Erdmann, Dirk; Chêne, Patrick

doi:10.3109/14756366.2011.583922

Cited by 2 publications

(1 citation statement)

References 31 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…IGF1R tyrosine kinase inhibitors (TKIs) are small molecules that either bind to the receptor competitively with ATP, e.g. PQIP, the forerunner of OSI-906 (Linsitinib) (Ji et al 2007, Mulvihill et al 2009), the structurallyrelated compound NVP-AEW541 (Brockhoff et al 2012), BMS-754807 (Carboni et al 2009) and BI 885578 (Sanderson 2015) or inhibit in a non-ATP-competitive manner, e.g. picropodophyllin or PPP (Girnita et al 2004).…”

Section: Igf1r-targeted Therapies: Mechanism Of Actionmentioning

confidence: 99%

Combination therapy approaches to target insulin-like growth factor receptor signaling in breast cancer

Ochnik

Baxter

2016

Endocrine-Related Cancer

View full text Add to dashboard Cite

Insulin-like growth factor receptor (IGF1R) signaling as a therapeutic target has been widely studied and clinically tested. Despite the vast amount of literature supporting the biological role of IGF1R in breast cancer, effective clinical translation in targeting its activity as a cancer therapy has not been successful. The intrinsic complexity of cancer cell signaling mediated by many tyrosine kinase growth factor receptors that work together to modulate each other and intracellular downstream mediators in the cell highlights that studying IGF1R expression and activity as a prognostic factor and therapeutic target in isolation is certainly associated with problems. This review discusses the current literature and clinical trials associated with IGF-1 signaling and attempts to look at new ways of designing novel IGF1R-directed breast cancer therapy approaches to target its activity and/or intracellular downstream signaling pathways in IGF1R-expressing breast cancers. 23:11 Review A M Ochnik and R C BaxterDual IGF-directed breast cancer therapies

show abstract